Ayse Nihal Sari Selected Research

N-(20-hydroxyeicosa-5,14-dienoyl)glycine

1/2022	Activation of GPR75 Signaling Pathway Contributes to the Effect of a 20-HETE Mimetic, 5,14-HEDGE, to Prevent Hypotensive and Tachycardic Responses to Lipopolysaccharide in a Rat Model of Septic Shock.
5/2016	Contribution of PPARα/β/γ, AP-1, importin-α3, and RXRα to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against hypotension, tachycardia, and inflammation in a rat model of septic shock.
9/2013	Contribution of iNOS/sGC/PKG pathway, COX-2, CYP4A1, and gp91(phox) to the protective effect of 5,14-HEDGE, a 20-HETE mimetic, against vasodilation, hypotension, tachycardia, and inflammation in a rat model of septic shock.
4/2013	5,14-HEDGE, a 20-HETE mimetic, reverses hypotension and improves survival in a rodent model of septic shock: contribution of soluble epoxide hydrolase, CYP2C23, MEK1/ERK1/2/IKKβ/IκB-α/NF-κB pathway, and proinflammatory cytokine formation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ayse Nihal Sari Research Topics

Disease

9	Hypotension (Low Blood Pressure) 01/2022 - 09/2011
9	Inflammation (Inflammations) 03/2021 - 01/2012
8	Septic Shock (Toxic Shock Syndrome) 01/2022 - 01/2012
4	Tachycardia (Tachyarrhythmias) 01/2022 - 04/2013
3	Hyperalgesia 03/2021 - 04/2017
2	Pain (Aches) 03/2021 - 01/2021
2	Shock 01/2019 - 09/2011
2	Sepsis (Septicemia) 05/2017 - 01/2012
2	Endotoxemia 05/2016 - 07/2013
1	Arteritis 01/2022
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2022
1	Necrosis 01/2019
1	Neoplasms (Cancer) 05/2017
1	Metabolic Diseases (Metabolic Disease) 05/2017
1	Multiple Organ Failure (MODS) 09/2011

Drug/Important Bio-Agent (IBA)

9	LipopolysaccharidesIBA 01/2022 - 01/2012
7	20-hydroxy-5,8,11,14-eicosatetraenoic acidIBA 01/2022 - 09/2011
5	Vasodilator Agents (Vasodilators)IBA 01/2019 - 01/2012
4	N-(20-hydroxyeicosa-5,14-dienoyl)glycineIBA 01/2022 - 04/2013
4	Glycine (Aminoacetic Acid)FDA LinkGeneric 01/2022 - 01/2012
3	CytokinesIBA 03/2021 - 01/2012
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 07/2013
3	Prostaglandin-Endoperoxide Synthases (Cyclooxygenase)IBA 01/2019 - 09/2011
3	Nitric Oxide (Nitrogen Monoxide)FDA Link 05/2017 - 09/2011
3	Peroxynitrous Acid (Peroxynitrite)IBA 05/2017 - 07/2013
3	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 05/2017 - 01/2012
2	InflammasomesIBA 01/2021 - 04/2017
2	Epoxide HydrolasesIBA 01/2021 - 04/2013
2	NucleotidesIBA 01/2021 - 04/2017
2	Caspase 1 (ICE Protease)IBA 01/2021 - 04/2017
2	Nitric Oxide Synthase (NO Synthase)IBA 01/2019 - 09/2011
2	ZymosanIBA 01/2019 - 02/2018
2	NADP (NADPH)IBA 02/2018 - 04/2017
2	EnzymesIBA 05/2017 - 09/2013
2	EicosanoidsIBA 07/2013 - 01/2012
2	ProstaglandinsIBA 07/2013 - 01/2012
2	EndotoxinsIBA 01/2012 - 09/2011
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022
1	Bexarotene (LGD1069)FDA Link 03/2021
1	Neuroprotective AgentsIBA 03/2021
1	InterleukinsIBA 01/2021
1	14,15-dihydroxyeicosatrienoic acidIBA 01/2021
1	2- (7- (3,4- dimethoxyphenyl)imidazo(1,2- c)pyrimidin- 5- ylamino)nicotinamideIBA 01/2019
1	Syk KinaseIBA 01/2019
1	Interleukin-8 (Interleukin 8)IBA 01/2019
1	NADPH Oxidases (NAD(P)H oxidase)IBA 02/2018
1	Phosphotransferases (Kinase)IBA 02/2018
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 02/2018
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 02/2018
1	Peroxidase (Myeloperoxidase)IBA 05/2017
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 05/2017
1	TOR Serine-Threonine KinasesIBA 05/2017
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 05/2017
1	Epoprostenol (Prostacyclin)FDA LinkGeneric 05/2017
1	Ribosomal Protein S6IBA 05/2017
1	Toll-Like Receptor 4IBA 05/2017
1	CaspasesIBA 04/2017
1	3-nitrotyrosineIBA 04/2017
1	Protein Isoforms (Isoforms)IBA 04/2017
1	Leucine-Rich Repeat ProteinsIBA 04/2017
1	Oxidoreductases (Dehydrogenase)IBA 04/2017
1	N- (1,2,3,5,6,7- hexahydro- S- indacen- 4- ylcarbamoyl)- 4- (2- hydroxy- 2- propanyl)- 2- furansulfonamideIBA 04/2017
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 05/2016
1	Superoxides (Superoxide)IBA 09/2013
1	Cyclic GMP-Dependent Protein Kinases (Protein Kinase G)IBA 09/2013
1	4- ethoxymethylene- 2- phenyl- 2- oxazoline- 5- one (phOx)IBA 09/2013
1	Soluble Guanylyl CyclaseIBA 09/2013
1	Dinoprostone (PGE2)FDA Link 07/2013
1	N- (2- cyclohexyloxy- 4- nitrophenyl)methanesulfonamideIBA 07/2013
1	NitrogenIBA 01/2012
1	Lipid AIBA 01/2012
1	Hydroxyeicosatetraenoic Acids (HETE)IBA 01/2012
1	Oxygen (Dioxygen)IBA 01/2012
1	Piroxicam (Feldene)FDA LinkGeneric 09/2011
1	Cytochrome P-450 Enzyme System (Cytochrome P450)IBA 09/2011

Therapy/Procedure

4	Controlled Hypotension 01/2022 - 01/2012
1	Resuscitation 01/2012